Glypican 3 antibody drug conjugate - Bristol-Myers Squibb
Latest Information Update: 15 Feb 2017
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Glypican 3 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 14 Feb 2017 Phase-I clinical trials in Cancer in USA (Parenteral) before February 2017 (Bristol-Myers Squibb pipeline, February 2017)